Clinical Trials · NCT00477490
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 799
- Start date
- May 2007
- Locations
- 80 sites, United States, Canada
- Primary endpoint
- Part I: Change From Baseline in Mean Number of Nocturnal Voids at Week 4